Mackey David A, Hewitt Alex W
aLions Eye Institute, Centre for Ophthalmology and Visual Science, University of Western Australia, Perth, Western Australia bCentre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, University of Melbourne, Melbourne, Victoria cSchool of Medicine, Menzies Research Institute Tasmania, University of Tasmania, Hobart, Tasmania, Australia.
Curr Opin Ophthalmol. 2014 Sep;25(5):386-93. doi: 10.1097/ICU.0000000000000090.
Much progress in our understanding of the genetic profile of many ophthalmic diseases has been made over the last decade. Identification of novel gene associations allows insight into the mechanisms of disease and potentially enables the identification of individuals at increased risk, as well as facilitating the development of new treatments. We highlight key recent discoveries using the genome-wide association study design.
Over the last 2 years, we have seen major international collaborations successfully conduct genome-wide association study to identify genetic pathways associated with eye diseases, such as myopia, age-related macular degeneration and glaucoma. Similarly other studies have identified and confirmed genes associated with ocular biometry or disease-specific endophenotypes.
Our understanding of the genetic architecture of common eye diseases, such as myopia, age-related macular degeneration and glaucoma, is rapidly expanding. With reducing costs of next-generation sequencing, we expect a transition to large-scale interrogation at the whole exome and genome level, which will enable the identification of rare variants which confer a level of sensitivity and specificity to predict risk that will allow us to further understand, predict and intervene in genetic-based eye diseases.
在过去十年中,我们对许多眼科疾病的基因图谱的理解取得了很大进展。确定新的基因关联有助于深入了解疾病机制,并有可能识别出患病风险增加的个体,同时也促进新治疗方法的开发。我们重点介绍近期使用全基因组关联研究设计的关键发现。
在过去两年中,我们看到主要的国际合作成功开展了全基因组关联研究,以确定与眼部疾病相关的遗传途径,如近视、年龄相关性黄斑变性和青光眼。同样,其他研究也已识别并确认了与眼生物测量或疾病特异性内表型相关的基因。
我们对常见眼科疾病(如近视、年龄相关性黄斑变性和青光眼)的遗传结构的理解正在迅速扩展。随着下一代测序成本的降低,我们预计将过渡到在全外显子组和基因组水平进行大规模检测,这将能够识别出具有一定敏感性和特异性的罕见变异,从而预测风险,使我们能够进一步了解、预测和干预基于遗传的眼部疾病。